An open label phase-IV, label expansion study to evaluate the safety and immunogenicity of BE's licensed Inactivated vero cell based Japanese Encephalitis Vaccine in 3 to 18 year old Indian children amp; adolescents in a two dose (0, 28D) schedule.

Trial Profile

An open label phase-IV, label expansion study to evaluate the safety and immunogenicity of BE's licensed Inactivated vero cell based Japanese Encephalitis Vaccine in 3 to 18 year old Indian children amp; adolescents in a two dose (0, 28D) schedule.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs IC 51 (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions
  • Sponsors Biological E Limited
  • Most Recent Events

    • 06 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top